| Objective: To study dendritic cells (DC) precursors that were mobilized into the peripheral blood by injection of macrophage inflammation protein-1α(MIP-1α) and the anti-tumor effects induced by MIP-1αmobilized DC vaccine expressing tumor antigen in vivo.Methods: (1) 615 mice were injected with MIP-1αvia the tail vein. The peripheral blood was obtained at the different time intervals after MIP-1αinjection. The peripheral blood mononuclear cells (MNCs) were prepared from the peripheral blood. B220~-CD11c~+ cells were sorted from these MNCs by FACS. Then compare the quantitive change of B220~-CD11c~+ cells among MNCs. (2) Freshly isolated B220~-CD11c~+ cells and B220~-CD11c~+ cells cultured with mouse granulocyte-macrophage colony-stimulating factor (mGM-CSF), interleukin 4 (IL-4), and mouse tumor necrosis factor-α(mTNF-α) were analysed by morphological observation, phenotype analysis, and mixed lymphocyte reaction (MLR). (3) For adenoviral (Ad)-mediated gene transduction, cultured B220~-CD11c~+ cells were incubated with Ad-melanoma antigen gene-3 (Ad-MAGE-3). MIP-1αmobilized B220~-CD11c~+ cells pulsed (mouse forestomach carcinima, MFC) cells tumor lysate (MIP-1α-DC-MFC Ag) were used as positive control. (4) To establish the solid tumor model, groups of 615 mice were injected with MFC cells subcutaneously in the abodminal wall. MIP-1αmobilized DC vaccine expressing tumor antigen were immuned before and after the challenge of MFC cells, then we observed the tumor size and the survival of mice which could detect the protective and therapeutic effect of DC vaccines.Results: (1) B220~-CD11c~+ cells increased in the circulation 8 hour after MIP-1αinjection, then gradually reached a peak level 48 hour after injection, account for 13.68%±0.95% among MNC of the peripheral blood. (2) Freshly isolated B220~-CD11c~+ cells did not show... |
